Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
2023年11月1日 - 1:00AM
Amarin Corporation plc (NASDAQ:AMRN) today announced the
appointment of Jonathan Provoost as the Company's new Executive
Vice President, Chief Legal & Compliance Officer. He will join
the Company on November 15.
Mr. Provoost, who most recently served as Vice
President, General Counsel and Chief Compliance Officer at Tris
Pharma, Inc., brings more than 20 years of corporate legal
experience, having served most of his career in large and
medium-sized pharmaceutical companies.
"We are excited to welcome Jonathan to Amarin,
where he will serve as an integral part of our leadership team and
will be responsible for helping define and execute our ongoing
legal and compliance strategy to support our key priorities," said
Patrick Holt, President & CEO, Amarin. "Jonathan's depth of
experience with corporate and compliance matters, as well former
leadership roles managing intellectual property, complex
litigation, business development and transactional matters, will
provide the right mix of capabilities to help support Amarin and
our future path."
Mr. Provoost’s broad experience in the legal profession includes
serving as Chief Compliance Officer and General Counsel, management
of intellectual property, general transactions, litigation, and
various business activities. Throughout Jonathan’s career he has
enjoyed positions of increasing managerial responsibility, and most
recently, served as Vice President, General Counsel and Chief
Compliance Officer at Tris Pharma, Inc. Prior to Tris, Jonathan
served as General Counsel for Business Development & Licensing
at Mallinckrodt Pharmaceuticals following a number of roles of
increasing responsibility at the company. Earlier in his career,
Mr. Provoost served in various legal roles for other pharmaceutical
companies, including Ikaria, Inc., Kos Pharmaceuticals and
Bristol-Myers Squibb. Jonathan earned his J.D. from Pace University
School of Law, his M.B.A. from Lehigh University, and a B.S. in
Chemistry from SUNY Oswego, in addition to serving in the U.S.
Marine Corps Reserve. He is admitted to NY/NJ bars and is
registered to practice before the U.S. Patent and Trademark Office
(USPTO).
About
Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. We are committed to
increasing the scientific understanding of the cardiovascular risk
that persists beyond traditional therapies and advancing the
treatment of that risk for patients worldwide. Amarin has offices
in Bridgewater, New Jersey in the United States, Dublin in Ireland,
Zug in Switzerland, and other countries in Europe as well as
commercial partners and suppliers around the world.
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, including key priorities
and the overall potential and future success of VASCEPA (marketed
as VAZKEPA in Europe) and Amarin generally. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. A further list and description of these
risks, uncertainties and other risks associated with an investment
in Amarin can be found in Amarin's filings with the U.S. Securities
and Exchange Commission (the “SEC”), including Amarin’s annual
report on Form 10-K for the full year ended 2022, subsequently
filed quarterly reports on Form 10-Q (including the upcoming
quarterly report for the quarter ended September 30, 2023), current
reports on Form 8-K and other filings made by Amarin with the SEC.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date they are made. Amarin undertakes no obligation to
update or revise the information contained in its forward-looking
statements, whether as a result of new information, future events
or circumstances or otherwise. Amarin’s forward-looking statements
do not reflect the potential impact of significant transactions the
company may enter into, such as mergers, acquisitions,
dispositions, joint ventures or any material agreements that Amarin
may enter into, amend or terminate.
Availability of Other Information About
Amarin
Amarin communicates with its investors and the public using the
company website (www.amarincorp.com) and the investor relations
website (investor.amarincorp.com), including but not limited to
investor presentations and FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact
Information Investor
Inquiries: Jordan Zwick Amarin Corporation
plc IR@amarincorp.com Media
Inquiries: Mark Marmur Amarin Corporation
plc PR@amarincorp.com
Amarin (NASDAQ:AMRN)
過去 株価チャート
から 4 2024 まで 5 2024
Amarin (NASDAQ:AMRN)
過去 株価チャート
から 5 2023 まで 5 2024